EPISODE · Apr 27, 2026 · 2 MIN
Vyvgart Crosses the Antibody Line in Seronegative Myasthenia Gravis
from TheBrief.Health · host TheBrief.Health
Phase 3 ADAPT SERON data show efgartigimod improves function in seronegative generalized myasthenia gravis, with FDA priority review potentially expanding targeted treatment options for underserved patients.
What this episode covers
Phase 3 ADAPT SERON data show efgartigimod improves function in seronegative generalized myasthenia gravis, with FDA priority review potentially expanding targeted treatment options for underserved patients.
NOW PLAYING
Vyvgart Crosses the Antibody Line in Seronegative Myasthenia Gravis
No transcript for this episode yet
Similar Episodes
Apr 21, 2026 ·13m
Apr 19, 2026 ·16m
Apr 17, 2026 ·13m
Apr 13, 2026 ·11m
Apr 11, 2026 ·16m